Royalty Pharma (RPRX) Financials

Royalty Pharma’s recent results show a business with steadily growing royalty revenue but volatile reported profitability. Revenue reached $674.1 million in Q2 2026, up 6.9% from Q1 2026 and 16.5% from Q2 2025. The company’s royalty-focused model continues to produce substantial operating cash flow, although earnings attributable to common shareholders have fluctuated sharply because of operating adjustments, financing costs and the large share of income allocated to noncontrolling interests.

Profitability weakened materially in Q2 2026. Operating income fell to $133.1 million from $563.0 million in Q1 2026, while net income attributable to common shareholders declined to $17.9 million from $294.7 million. Diluted earnings per share fell to $0.04 from $0.67 in the prior quarter and $0.07 in Q2 2025. The primary driver was a swing in other operating expenses from a $201.2 million benefit in Q1 to a $281.3 million expense in Q2. This illustrates the volatility in Royalty Pharma’s reported earnings despite relatively consistent revenue.

Cash generation remains a more favorable part of the financial picture. Net cash from operating activities was $728.5 million in Q2 2026, compared with $718.2 million in Q1 and $364.0 million in Q2 2025. However, the company continues to deploy substantial cash into investments and shareholder returns. Q2 investing cash flow was negative $229.7 million, while dividends and share repurchases consumed approximately $270.3 million in financing cash flow.

The balance sheet has expanded over the period, with total assets increasing from $15.9 billion in Q3 2023 to $19.8 billion in Q2 2026. Most assets consist of note and lease receivables, including $16.2 billion of noncurrent receivables. Cash and equivalents stood at $812.0 million at June 30, 2026, up from $586.4 million at the end of Q1 but well below the $2.17 billion reported in Q2 2023.

Royalty Pharma maintains a sizable liquidity cushion: current assets of $1.76 billion exceeded current liabilities of $630.9 million by roughly 2.8 times. Still, debt has increased over the longer period. Short- and long-term debt totaled approximately $9.0 billion in Q2 2026, compared with roughly $6.1 billion of long-term debt and no short-term debt in Q3 2023. Interest expense of $93.6 million in Q2 2026 remains a meaningful claim on pretax income.

• Revenue growth remains intact: Q2 2026 revenue of $674.1 million was the highest among the reported quarters and increased 16.5% year over year.
• Operating cash flow is strong: Royalty Pharma generated $728.5 million of operating cash in Q2 2026, nearly matching the prior quarter and doubling the Q2 2025 level.
• Liquidity is adequate: Cash, short-term investments and other current assets provide a sizable buffer over current liabilities, with a current ratio of approximately 2.8.
• Shareholder distributions continue: The company paid $225.7 million in dividends and repurchased $44.6 million of stock in Q2 2026; the quarterly dividend per share increased from $0.20 in Q1 2023 to $0.235 in Q1 2026.
• Assets continue to grow: Total assets rose to $19.8 billion, but the increase is concentrated in note and lease receivables, so investors should monitor the timing and quality of royalty-related cash collections.
• Reported results are difficult to compare: Several historical income and cash flow periods are marked as restated, and some cash flow figures show unusually large noncash adjustments. Underlying trends should therefore be evaluated alongside company-reported non-GAAP measures.
• Common-shareholder earnings are highly volatile: Q2 2026 diluted EPS of $0.04 was down from $0.67 in Q1 2026 and $0.08 in Q2 2025, despite higher revenue.
• Operating margins deteriorated sharply: Q2 operating income was $133.1 million, or about 19.7% of revenue, versus approximately 89.3% in Q1 2026 and 36.2% in Q2 2025.
• Leverage has increased: Total debt was approximately $8.96 billion at June 30, 2026, while quarterly interest expense remained above $93 million.
• Investment and distribution spending can pressure cash: Royalty acquisitions and investments have repeatedly produced large cash outflows, and dividends plus buybacks exceeded $270 million in Q2 2026.